Taiho Ventures logo

Taiho Ventures

North America, California, United States, California City

Description

Taiho Ventures is a company that specializes in the research and development of pharmaceuticals.

Investor Profile

Taiho Ventures has made 34 investments, with 4 in the past 12 months and 29% as lead.

Stage Focus

  • Series A (38%)
  • Series B (24%)
  • Series C (15%)
  • Seed (12%)
  • Series Unknown (9%)
  • Series D (3%)

Country Focus

  • United States (68%)
  • United Kingdom (18%)
  • The Netherlands (6%)
  • Japan (3%)
  • China (3%)
  • Germany (3%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science
  • Pharmaceutical
  • Biopharma
  • Oncology
  • Clinical Trials
  • Personal Health
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Taiho Ventures frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 4
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 4
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 4
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 4
NS Investment
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 3
MPM Capital
North America, Massachusetts, United States, Boston
Co-Investments: 5
ArrowMark Partners
North America, Colorado, United States, Denver
Co-Investments: 3
The Column Group
North America, California, United States, San Francisco
Co-Investments: 4
Foresite Capital
North America, California, United States, San Francisco
Co-Investments: 5
M Ventures
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 7

What are some of recent deals done by Taiho Ventures?

Normunity

New Haven, Connecticut, United States

Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.

BiotechnologyMedicalOncologyTherapeutics
Series BJan 13, 2025
Amount Raised: $75,000,000
Light Horse Therapeutics

San Diego, California, United States

Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.

Biotechnology
Series AJan 9, 2025
Amount Raised: $62,000,000
Libero Thera

Nihombashi-hamacho, Tokyo, Japan

Libero Thera provides drug discovery research and development services.

BiopharmaBiotechnologyLife ScienceMedical
Series UnknownAug 1, 2024
Amount Raised: $1,340,382
Theolytics

Oxford, Oxfordshire, United Kingdom

Theolytics is a clinical stage biotechnology company developing next-generation viral therapies.

BiotechnologyMedicalTherapeutics
Series UnknownApr 17, 2024
Amount Raised: $23,660,858
Theolytics

Oxford, Oxfordshire, United Kingdom

Theolytics is a clinical stage biotechnology company developing next-generation viral therapies.

BiotechnologyMedicalTherapeutics
Series AAug 25, 2023
Amount Raised: $27,797,378
EpiBiologics

San Mateo, California, United States

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

BiotechnologyHealth CareMedicalTherapeutics
Series AJul 20, 2023
Amount Raised: $23,000,000
Anavo Therapeutics

Leiden, Zuid-Holland, The Netherlands

Anavo Therapeutics provides therapeutic potential of human phosphatase biology.

BiotechnologyLife ScienceTherapeutics
SeedMay 2, 2023
Amount Raised: $9,358,986
Cellvie

Houston, Texas, United States

Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.

BiotechnologyLife ScienceTherapeutics
SeedFeb 6, 2023
Amount Raised: $5,500,000
Storm Therapeutics

Cambridge, Cambridgeshire, United Kingdom

Targeting pathways that modify RNA to deliver novel cancer therapeutics

BiotechnologyHealth CareMedicalTherapeutics
Series BDec 14, 2022
Amount Raised: $30,000,000
hC Bioscience

Cambridge, Massachusetts, United States

HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.

BiotechnologyHealth CareLife Science
Series ANov 4, 2022
Amount Raised: $16,000,000